Morgan 2022.

Study characteristics
Methods	Phase II, multicentre, open‐label randomised trial
Participants	Country: USA Period of recruitment: not reported Number randomised: 34 Postrandomisation dropouts: 0 Revised sample size: 34 Average age (years): not reported Males: not reported Decompensated cirrhosis:100% Alcohol‐related cirrhosis: 100% Acute‐on‐chronic liver failure: 100% Alcohol‐related cirrhosis 100% Viral‐related cirrhosis: 0% Autoimmune disease‐related cirrhosis: 0% Other causes of cirrhosis: 0% Inclusion criteria People with a clinical diagnosis of AH and a Maddrey discriminant function score ≥ 32 Exclusion criteria Not reported
Interventions	Experimental Pegfilgrastim* (0.6 mg subcutaneously) on day 1 and day 8, and standard of care Control Standard medical therapy alone All participants received standard medical therapy. Standard medical therapy: prednisolone *Pegfilgrastim: a long‐acting recombinant G‐CSF
Outcomes	Primary outcome Survival at day 90 Secondary outcomes Incidence of acute kidney injury Hepatorenal syndrome Hepatic encephalopathy Infections
Notes	Conflicts of interest: no information provided Funding: no information provided ClinicalTrials.gov number: NCT02776059 Published only in abstract
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	This open‐label trial randomised participants. No further information was given.
Allocation concealment (selection bias)	Unclear risk	No information was given.
Blinding of participants and personnel (performance bias) All outcomes	High risk	This was an open‐label study.
Blinding of outcome assessment (detection bias) overall mortality	Low risk	No information was given, but for the mortality outcome, low risk of bias.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information was given.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	All included participants were analysed.
Selective reporting (reporting bias)	Unclear risk	The trial reported all‐cause mortality as a primary outcome.
Other bias	Low risk	We found no other bias.